Inclusion Criteria:

- Patients or their health care proxies must be able to provide consent to participate
in this trial.

- Patients must have one of the following diagnoses which has not responded or recurred
following at least one prior chemotherapy regimen or radiation therapy:

- anaplastic astrocytoma, glioblastoma multiforme or oligodendroglioma

- primary CNS lymphoma

- malignant disease metastatic to the CNS

- Patients must be candidates for high dose chemotherapy and autologous stem cell
transplant according to the following criteria:

- Patients must be between the ages of 18 and 70 years (inclusive)

- Patients must have a left ventricular ejection fraction greater than or equal to
45% by MUGA or echocardiogram

- Patients must have adequate pulmonary function with FEV1, FVC and DLCO greater
than or equal to 50% of predicted

- Patients must have serum direct bilirubin less than or equal to 2.0 mg/dl and
transaminases less than or equal to 3x institutional upper limit of normal

- Patients must have serum creatinine less than or equal to 2 mg/dl with
creatinine clearance greater than or equal to 60 ml/min (either calculated or
measured)

- Patients must have an ECOG performance status between 0 and 2

- Patients must be at least 4 weeks from last cytoreductive chemotherapy.

- Expected survival of at least 3 months

Exclusion Criteria:

- Patients with uncontrolled metastatic disease outside of the CNS which would itself,
in the investigator's opinion, limit survival to less than 6 months

- Patients with uncontrolled seizures are ineligible.

- Patients with a history of myocardial infarction within the preceding 6 months,
significant arrhythmia within the preceding 3 months, or uncontrolled hypertension or
congestive heart failure are ineligible.

- Patients with unstable angina are ineligible.

- Pregnant or lactating women are ineligible.

- Male and female patients who do not agree to practice approved methods of birth
control for the duration of the study are ineligible.

- Patients with uncontrolled, active infection are ineligible.

- Patients infected with HIV are ineligible.